Financial Daily from THE HINDU group of publications
Wednesday, Jan 08, 2003

News
Features
Stocks
Port Info
Archives

Group Sites

Industry & Economy - Pharmaceuticals


Watershed year for diabetics

Sanjiv Shankaran


Ms Kiron Mazumdar-Shaw, Chairperson and Managing Director, Biocon India Ltd.

CHENNAI, Jan. 7

THE year 2003 may turn out to be a watershed for diabetics. It started with Eli Lilly (India) slashing the price of human insulin by 33 per cent in a single stroke. In a few months, Wockhardt and Biocon India plan to introduce human insulin in the domestic market.

"Our target date is October 2003," said Ms Kiron Mazumdar-Shaw, Chairman & Managing Director, Biocon India. Wockhardt is expected to launch its product by June.

A sharp drop in prices has followed the entry of domestic companies in biotech products such as vaccines.

In the case of human insulin, Eli Lilly moved from import to domestic production of insulin crystals, and used the cost-benefit to bring down the price of human insulin.

Talking to Business Line on the sidelines of a conference held here to promote a biotech event, Bangalore Bio 2003, Ms Shaw expressed surprise at the timing of the sharp drop in human insulin price. "We were prepared for a price slash, but we thought it could happen after we launched," said Ms Shaw.

According to Mr Rajiv Gulati, Chairman and Managing Director, Eli Lilly, about 70 per cent of the cost of insulin comprises storage equipment such as vials and cold chain system that is imported by Eli Lilly to meet its parent's manufacturing standard.

Subsequent reduction in the price of human insulin would depend on the sourcing of storage equipment. Biocon's insulin project operates through a 50:50 joint venture with Shanta Biotechnics.

The joint venture has a combined investment of Rs 25 crore, and proposes to carry out bulk of the production at Biocon's facilities and packaging at Shanta Bio's facilities.

Diabetes is forecast to reach epidemic proportion in India, thereby, attracting competition in the market for medicines.

Mr Gulati forecast that about 20 per cent of the diabetics in the world by 2025 would be Indians.

Send this article to Friends by E-Mail
Comment on this article to BLFeedback@thehindu.co.in

Stories in this Section
Lack of will hampering growth, says Prahalad


`Retail financial services can rev up economy'
Will the Bush package make a difference?
Tax reforms vital for 8% growth, says CII
Kerala: Panel moots Bill for increasing tree cover
K-G find spurs plans for fertiliser units
Biscuit industry sticks to tried and tested recipes
Czechoslovakia keen to expand trade contacts
AP: Rs 12,000-cr refinery among 41 MoUs worth Rs 17,204 cr signed
Vizag-Hyderabad LPG pipeline
Watershed year for diabetics
TNEB to get more thermal coal via coastal route
`Modify credit norms for SSIs'
Codissia in spot over trade fair complex — Seeks grant to meet SIDBI commitments
Bickering Ministries hold up HPCL divestment
Nations must innovate, patent IPRs
`GDP may run upstream thru river link' — Mr Suresh Prabhu, Chairman, Task Force on Linking of Rivers
Muthiah calls for review of Securitisation Act
Kerala: Investors' meet attracts 560 delegates so far
Thiruvananthapuram Engagement
Chandak to head SAFA


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright 2003, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line